Jan 10, 2024 / 12:30AM GMT
Jess Fye JPMorgan-Analyst
Hey there. Good afternoon, everyone. My name's Jess Fye. I'm a senior biotech analyst at JPMorgan. And we're continuing the 42nd Annual Healthcare Conference today with Deciphera.
I'm joined by the company's CEO, Steve Hoerter. He's going to give a presentation on the business, and then we're going to go right into Q&A. (Conference Instructions)
So with that, let me pass it over to Steve.
Steve Hoerter Deciphera Pharmaceuticals - Inc. - President & CEO
Great. Thank you, Jess. Good afternoon, everybody. It's really exciting to be here back at the conference. And I want to thank Jess and the team at JPMorgan for the very kind invitation to join again for this year's conference.
And I'm excited as well to provide an update on the great progress that we're making at Deciphera. We had a fantastic year in 2023. And during today's remarks, I'll outline our milestones for 2024, as we are now on the cusp of transitioning to a company with multiple approved medicines and on a path to becoming a self
Deciphera Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers